Toshiba rolls out ultrasound upgrade
Toshiba American Medical Systems of Tustin, CA, last month introduced the next generation of its mid-range ultrasound scanners at the American College of Cardiology conference in New Orleans. PowerVision 6000edp (expanded digital performance) allows
Toshiba American Medical Systems of Tustin, CA, last month introduced the next generation of its mid-range ultrasound scanners at the American College of Cardiology conference in New Orleans. PowerVision 6000edp (expanded digital performance) allows users to select multifrequency tissue harmonics that best match the size of the patient and acoustic access, and incorporates technological advancements in Doppler performance and color maps for cardiac and vascular applications.
Other technologies available on the system include Toshibas version of harmonic imaging, called Flash Echo Imaging, and its latest version of Clear View Tissue Harmonics (CVTH). The company plans to provide the $30,000 PowerVision 6000edp as a free upgrade to facilities that already have PowerVision 6000 installed. Toshiba launched PowerVision 6000 last spring (SCAN 5/27/98).
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
